City of Hope | Strategic Alliance Partners

May 25, 2018

Maung Myo Htut, MD, assistant clinical professor of hematology and hematopoietic cell transplantation, City of Hope, discusses the use of immunotherapy in the treatment of patients with multiple myeloma.

May 10, 2018

Maurie Markman, MD, discusses the cause and impact of the opioid addiction epidemic in the United States.

April 23, 2018

City of Hope is currently the only institution in Southern California to offer both FDA-approved CAR T-cell therapies.

February 20, 2018

Ravi Salgia, MD, PhD, discusses the evolving role of ALK-directed therapies for patients with non-small cell lung cancer.

February 19, 2018

Ravi Salgia, MD, PhD, associate director, Clinical Sciences Research, Arthur & Rosalie Kaplan Chair, Medical Oncology, professor and chair, Department of Medical Oncology & Therapeutics Research, City of Hope, discusses effective agents in the treatment of patients with ALK-positive tumors.

February 15, 2018

Sagus Sampath, MD, assistant professor, Department of Radiation Oncology, City of Hope, discusses the safety profile of immunotherapy in combination with radiation in the treatment of patients with lung cancer.

February 06, 2018

Loretta Erhunmwunsee, MD, thoracic surgeon, assistant professor of surgery, City of Hope, discusses the factors that contribute to disparities in the treatment of patients with lung cancer.

February 01, 2018

Ravi Salgia, MD, PhD, Arthur & Rosalie Kaplan Chair in Medical Oncology, associate director for clinical sciences at City of Hope, discusses the importance of molecular markers in lung cancer.

January 31, 2018

Dan J. Raz, MD, MAS, co-director, Lung Cancer and Thoracic Oncology Program, assistant professor, Division of Thoracic Surgery, Department of Surgery, City of Hope, discusses the subsets of the ALCHEMIST trial.

January 31, 2018

Jae Y. Kim, MD, chief, Division of Thoracic Surgery, Department of Surgery, assistant professor, Department of Surgery, City of Hope, discusses the use of immune checkpoint inhibitors in surgical patients with lung cancer.

January 30, 2018

Erminia Massarelli, MD, PhD, MS, associate clinical professor, Department of Medical Oncology and Therapeutics Research, City of Hope, discusses the adoption of alectinib (Alecensa) as the first-line therapy in the treatment of patients with ALK-positive non–small cell lung cancer (NSCLC).

January 17, 2018

Loretta Erhunmwunsee, MD, thoracic surgeon, assistant professor of surgery, City of Hope, discusses disparities in the treatment of lung cancer.

January 16, 2018

Maurie Markman, MD, discusses the need to change the paradigm of clinical trials and FDA approvals in ovarian cancer.

January 08, 2018

Jae Y. Kim, MD, discusses developments with checkpoint inhibition in patients with resectable NSCLC.

January 05, 2018

Ravi Salgia, MD, PhD, discusses the evolution and current state of biomarker testing in the field of NSCLC.

January 02, 2018

Loretta Erhunmwunsee, MD, discusses the racial and socioeconomic disparities in lung cancer trials

December 13, 2017

City of Hope announced that it has appointed Michael A. Caligiuri, M.D., in a new executive leadership role as president of City of Hope National Medical Center and physician-in-chief.

November 17, 2017

Jonathan N. Warner, MD, reconstructive urologist, City of Hope, discusses the future of surgery for patients with prostate cancer.

November 14, 2017

Sumanta K. Pal, MD, discusses advancements in prostate cancer, bladder cancer, and promising results in kidney cancer.

September 19, 2017

Patients who received maintenance therapy with rituximab (Rituxan) following autologous stem cell transplantation as treatment for mantle cell lymphoma had a survival advantage, according to results from a retrospective single-center study.